scholarly journals Polyphenols as Possible Agents for Pancreatic Diseases

Antioxidants ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 547
Author(s):  
Uroš Gašić ◽  
Ivanka Ćirić ◽  
Tomislav Pejčić ◽  
Dejan Radenković ◽  
Vladimir Djordjević ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Early Diagnosis ◽  
Pancreatic Disease ◽  
Biologically Active ◽  
Cytostatic Agents ◽  
Inhibitory Effects ◽  
Pancreatic Diseases ◽  
Anticancer Effects ◽  
Significant Data

Pancreatic cancer (PC) is very aggressive and it is estimated that it kills nearly 50% of patients within the first six months. The lack of symptoms specific to this disease prevents early diagnosis and treatment. Today, gemcitabine alone or in combination with other cytostatic agents such as cisplatin (Cis), 5-fluorouracil (5-FU), irinotecan, capecitabine, or oxaliplatin (Oxa) is used in conventional therapy. Outgoing literature provides data on the use of polyphenols, biologically active compounds, in the treatment of pancreatic cancer and the prevention of acute pancreatitis. Therefore, the first part of this review gives a brief overview of the state of pancreatic disease as well as the procedures for its treatment. The second part provides a detailed overview of the research regarding the anticancer effects of both pure polyphenols and their plant extracts. The results regarding the antiproliferative, antimetastatic, as well as inhibitory effects of polyphenols against PC cell lines as well as the prevention of acute pancreatitis are presented in detail. Finally, particular emphasis is given to the polyphenolic profiles of apples, berries, cherries, sour cherries, and grapes, given the fact that these fruits are rich in polyphenols and anthocyanins. Polyphenolic profiles, the content of individual polyphenols, and their relationships are discussed. Based on this, significant data can be obtained regarding the amount of fruit that should be consumed daily to achieve a therapeutic effect.

Determination of Plasma Glycoprotein 2 Levels in Patients With Pancreatic Disease

2004 ◽  
Vol 128 (6) ◽  
pp. 668-674 ◽  
Author(s):  
Ying Hao ◽  
Jing Wang ◽  
Ningguo Feng ◽  
Anson W. Lowe
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Tertiary Care ◽  
Pancreatic Disease ◽  
Pancreatic Acinar Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Assay Sensitivity ◽  
Acute And Chronic Pancreatitis

Abstract Context.—Blood tests possessing higher diagnostic accuracy are needed for all the major pancreatic diseases. Glycoprotein 2 (GP2) is a protein that is specifically expressed by the pancreatic acinar cell and that has previously shown promise as a diagnostic marker in animal models of acute pancreatitis. Objective.—This study describes the development of an assay for GP2, followed by the determination of plasma GP2 levels in patients with acute pancreatitis, chronic pancreatitis, and pancreatic cancer. Design.—Rabbit polyclonal antisera and mouse monoclonal antibodies were generated against human GP2 and used to develop an enzyme-linked immunosorbent assay. The assay was tested in patients with an admitting diagnosis of pancreatic disease at 2 tertiary care facilities. The diagnosis of acute or chronic pancreatitis and pancreatic cancer was determined using previously established criteria that incorporated symptoms, radiology, pathology, and serology. Plasma GP2 levels were determined in 31 patients with acute pancreatitis, 16 patients with chronic pancreatitis, 36 patients with pancreatic cancer, and 143 control subjects without pancreatic disease. Amylase and lipase levels were also determined in patients with acute pancreatitis. Results.—The GP2 assay's sensitivity values were 0.94 for acute pancreatitis, 0.81 for chronic pancreatitis, and 0.58 for pancreatic cancer, which were greater than the 0.71 for acute pancreatitis and 0.43 for chronic pancreatitis (P = .02) observed for amylase. The lipase assay sensitivity for acute pancreatitis was 0.66. The accuracy of the GP2 assay was greater than that of the amylase or lipase assays for acute pancreatitis (GP2 vs lipase, P = .004; GP2 vs amylase, P = .003) when analyzed using receiver operator characteristic curves. When daily serial blood samples were obtained for 13 patients with acute pancreatitis, GP2 levels remained abnormally elevated for at least 1 day longer than the amylase or lipase levels. Conclusion.—The GP2 assay is a useful new marker for acute and chronic pancreatitis.

Pancreatic disease

2011 ◽  
pp. 611-618
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Pancreatic Enzyme ◽  
Pancreatic Disease ◽  
Enzyme Replacement ◽  
Pancreatic Enzyme Replacement Therapy ◽  
Pancreatic Disorders

Pancreatic disorders 612 Pancreatic enzyme replacement therapy 616 See Table 27.1. The major pancreatic disorders include pancreatitis and pancreatic cancer. Pancreatitis results from the auto-digestion of the pancreas by activated pancreatic enzymes. It can be categorized as: • Chronic pancreatitis (CP). • Acute pancreatitis: •...

scholarly journals Fox sign in a case of terminal stage pancreatic cancer and suggestions for diagnosis

2021 ◽  
Author(s):  
Julian Prangenberg ◽  
Elke Doberentz ◽  
Burkhard Madea
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Medical Malpractice ◽  
Pancreatic Disease ◽  
Immunohistochemical Method ◽  
Diaper Dermatitis ◽  
Cutaneous Manifestations ◽  
Terminal Stage ◽  
The Right ◽  
Skin Signs

Abstract Skin signs in acute pancreatitis are well-known and frequently discussed manifestations accompanied by unfavorable prognoses although they may rarely appear in clinical and forensic medicine. In 2018, the district attorney’s office ordered a forensic autopsy for a 74-year-old man with terminal stage pancreatic cancer. The autopsy was ordered based on accusations of the deceased’s widow regarding alleged medical malpractice and poor hospital care. The widow filed a grievance about multiple unsuccessful attempts to draw blood from her husband in addition to a diaper dermatitis at the right groin. An autopsy and additional histological examinations were performed. After considering all findings, the diaper dermatitis was eventually assumed to be a Fox sign caused by acute pancreatitis, and the allegations of medical malpractice were refuted. This case led us to identify another case with suspected cutaneous manifestations in pancreatic disease. We performed immunohistochemical staining on those two cases and six control cases to examine whether there was detectable presence of pancreatic lipase and trypsin in the skin discolorations and whether it could be used as a feasible method to verify skin signs associated with pancreatitis. Based on our findings, a minor disseminated lipase and trypsin staining should be considered regular and is therefore not conclusive of a skin sign associated with pancreatitis. Moreover, trypsin does not seem to be as suitable as lipase for this suggested immunohistochemical method. Nevertheless, this method might be a useful addition for determining the origin of skin discoloration and verifying skin signs associated with pancreatitis.

Benign Exocrine Pancreatic Diseases in Inflammatory Bowel Diseases

2017 ◽  
Vol 35 (5) ◽  
pp. 449-453 ◽  
Author(s):  
Raffaele Pezzilli ◽  
Nico Pagano
Keyword(s):  
Acute Pancreatitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Pancreatic Disease ◽  
Disease Group ◽  
Pancreatic Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Group 3 ◽  
Group 2

Background: Data regarding the involvement of the pancreas during the course of inflammatory bowel disease (IBD) are scarce and conflicting. Aim: To assess the frequency of benign pancreatic diseases, that is, acute pancreatitis, chronic pancreatitis (CP), and autoimmune pancreatitis (AIP), in a population with IBD. Methods: A search for patients with IBD who presented at our hospital between January 2006 and January 2015 with a diagnosis of IBD was carried out. Patients: A total of 5,242 patients with IBD were included in this study (2,838 males, 54.1%, and 2,404 females, 45.9%, mean age 43.7 years, range 18-101 years). Of these 5,242 patients, 3,201 (61.1%) had Crohn's disease and 2,041 (38.9%) had ulcerative colitis (UC). Results: Thirteen patients developed benign pancreatic diseases (0.2%). Eight patients had acute pancreatitis (0.2%; 4 in the Crohn's disease group and 4 in the UC group), 3 had CP (0.1%, 2 in the Crohn's disease group and 1 in the UC group), 2 had AIP (0.04%), all in the group of diffuse UC (p = 0.321). Conclusions: The frequency of benign pancreatic disease was not high in patients with IBD and was probably similar to that seen in the general population.

Pancreatic Disease

2014 ◽  
pp. 748-756
Author(s):  
Alphonso Brown ◽  
Steven D. Freedman
Keyword(s):  
United States ◽  
Acute Pancreatitis ◽  
Annual Cost ◽  
Acute Inflammation ◽  
The United States ◽  
Pancreatic Disease ◽  
Common Condition ◽  
Worker Productivity ◽  
Pancreatic Diseases ◽  
Pancreatic Parenchyma

Acute pancreatitis may be defined as the development of acute inflammation of the pancreas initially localized to the pancreatic parenchyma and interstitium. It is a fairly common condition with an annual incidence of the United States of 80 cases per 100,000 individuals. Within the United States, the annual cost of hospital facilities for the treatment of pancreatic diseases is approximately $3.6–6 billion a year. There is also an annual cost to society of $250 million per year in lost worker productivity associated with hospitalization.

scholarly journals Prevalence of S and Z alpha 1-antitrypsin mutations in patients with pancreatic diseases in Serbian population

Genetika ◽  
2010 ◽  
Vol 42 (2) ◽  
pp. 377-385
Author(s):  
Aleksandra Nikolic ◽  
Aleksandra Divac ◽  
Marija Stankovic ◽  
Jelena Dinic ◽  
Snezana Lukic ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Pancreatic Cancer ◽  
Type 2 Diabetes Mellitus ◽  
Chronic Pancreatitis ◽  
Pancreatic Disease ◽  
Allelic Frequency ◽  
Pancreatic Diseases ◽  
Alpha 1 Antitrypsin

One of the key points in research of pancreatic disease pathology is further elucidation of the role of proteases and antiproteases, since their imbalance can lead to pancreatic injury. Alpha 1-antitrypsin (AAT) is one of the most important serum inhibitors of proteolytic enzymes, including pancreatic enzymes trypsin, chymotrypsin and elastase. It is speculated that mutations in the AAT gene may influence the onset and the development of pancreatic disease. The presence of the most common AAT mutations Z and S was analyzed in 160 patients with pancreatic diseases (50 patients with pancreatic cancer, 50 patients with chronic pancreatitis and 60 patients with type 2 diabetes mellitus) and 129 healthy individuals by PCR-mediated site-directed mutagenesis (PSM) method. One patient with pancreatic cancer was found to be a carrier of Z mutation, as well as one patient with type 2 diabetes mellitus. One patient with chronic pancreatitis was found to be a carrier of S mutation. The common AAT mutations were statistically significantly over-represented in patients with pancreatic diseases (3 of 160 patients, allelic frequency 0.9%) than in the control group (1 of 129 individuals, allelic frequency 0.4%). The results of this study, requiring confirmation, suggest that common AAT mutations Z and S may be associated with a modest increase in susceptibility to the development of pancreatic disease.

Potential predictors of pancreatic cancer: A population-based screen.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 164-164 ◽  
Author(s):  
E. Ragulin-Coyne ◽  
J. K. Smith ◽  
S. Ng ◽  
T. P. McDade ◽  
S. A. Shah ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Weight Loss ◽  
Acute Pancreatitis ◽  
Logistic Regression ◽  
Abdominal Pain ◽  
Chronic Pancreatitis ◽  
Bile Duct ◽  
Pancreatic Disease ◽  
Bile Duct Obstruction ◽  
Duct Obstruction

164 Background: Pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the U.S. Unfortunately, PC is usually diagnosed at late stages. We hypothesized that certain diagnoses may precede PC diagnosis and assist in early identification of pancreatic cancer patients. Methods: SEER-Medicare 1991-2005 was used to identify PC patients. PC and prePC diagnoses were identified using ICD9 codes. We then examined pre-pancreatic cancer (prePC) diagnoses and compared the frequency of those diagnoses by PC stage at time of cancer diagnosis. Stepwise logistic regression was used to assess potential PrePC diagnoses. Risk factors were compared by stage at diagnosis using Kruskal-Wallis test, stratified univariate analysis and logistic regression. Time to diagnosis was calculated for each PrePC diagnosis. Results: 19,801 PC patients were identified. Significant (p<0.05) prePC diagnoses included acute pancreatitis, chronic pancreatitis, cyst/pseudocyst, other pancreatic disease, bile duct obstruction, diabetes, weight loss, jaundice, abdominal pain, hepatomegaly. Median time (months) and interquartile range percentiles (25th-75th) before PC diagnosis were as follows: acute pancreatitis 0.97 (0.33-8.6), chronic pancreatitis 1.56 (0.37-11), cyst/pseudocyst 0.83 (0.3-3.5), other pancreatic disease 0.47 (0.2-1.2), bile duct obstruction 0.4 (0.17- 0.83), diabetes 30.6 (11.3-59.8), weight loss 1.16 (0.43-5.1), jaundice 0.43 (0.2-0.8), abdominal pain 16 (1.07-55.5), hepatomegaly 1.06 (0.33-1.07). Patients diagnosed at AJCC stage 0 had a mean of 3.53 prePC diagnoses (±SD 1.42); stage IA, 2.80 (1.68); stage IB, 2.42 (1.57); stage IIA, 2.44 (1.63); stage IIB, 2.46 (1.64); stage III, 2.33 (1.59); and Stage IV, 1.79 (1.40) (p<0.001). Conclusions: PC patients who presented at later stages were less likely to have prePC claims identified prior to PC diagnosis compared with patients diagnosed at earlier stages. This analysis of potential prePC diagnoses suggests that access to care and earlier identification of PC related conditions may factor into the stage at which this lethal disease is identified. Further studies need to be conducted to identify and analyze additional predictors of PC and better screen individuals at risk. No significant financial relationships to disclose.

scholarly journals A Proteomic Study on the Personalized Protein Corona of Liposomes. Relevance for Early Diagnosis of Pancreatic DUCTAL Adenocarcinoma and Biomarker Detection

2021 ◽  
Vol 2 (2) ◽  
pp. 82-93
Author(s):  
Luca Digiacomo ◽  
Francesca Giulimondi ◽  
Daniela Pozzi ◽  
Alessandro Coppola ◽  
Vincenzo La Vaccara ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Protein Corona ◽  
Detection Sensitivity ◽  
Ductal Adenocarcinoma ◽  
Protein Biomarkers ◽  
Ca 19.9 ◽  
Proteomic Study

Due to late diagnosis, high incidence of metastasis, and poor survival rate, pancreatic cancer is one of the most leading cause of cancer-related death. Although manifold recent efforts have been done to achieve an early diagnosis of pancreatic cancer, CA-19.9 is currently the unique biomarker that is adopted for the detection, despite its limits in terms of sensitivity and specificity. To identify potential protein biomarkers for pancreatic ductal adenocarcinoma (PDAC), we used three model liposomes as nanoplatforms that accumulate proteins from human plasma and studied the composition of this biomolecular layer, which is known as protein corona. Indeed, plasma proteins adsorb on nanoparticle surface according to their abundance and affinity to the employed nanomaterial, thus even small differences between healthy and PDAC protein expression levels can be, in principle, detected. By mass spectrometry experiments, we quantified such differences and identified possible biomarkers for PDAC. Some of them are already known to exhibit different expressions in PDAC proteomes, whereas the role of other relevant proteins is still not clear. Therefore, we predict that the employment of nanomaterials and their protein corona may represent a useful tool to amplify the detection sensitivity of cancer biomarkers, which may be used for the early diagnosis of PDAC, with clinical implication for the subsequent therapy in the context of personalized medicine.

Sign in / Sign up

Export Citation Format

Share Document